
Systemic antifungal fluconazole improves IBD symptoms by targeting gut Candida
A preliminary study from Weill Cornell Medicine indicates that the systemic antifungal fluconazole can improve symptoms in a subset of inflammatory bowel disease (IBD) patients by reducing intestinal Candida burden. Published in Nature Medicine, the research suggests that targeting fungal dysbiosis may restore gut microbial balance and reduce inflammation, offering a potential new therapeutic avenue for IBD management.


